Table 4. Outcomes in the treatment of recurrent primary central nervous system tumors.
Composite of multiple studies.
Abbreviations: CR, complete response; EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; MoA, mechanism of action; OS, overall survival; PFS, progression‐free survival; PR, partial response; q2w, every 2 weeks; q6w, every 6 weeks; SD, stable disease; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.